Merck's suvorexant meets Phase III insomnia endpoints

Merck & Co. Inc. (NYSE:MRK) reported positive data from two identical Phase III trials evaluating high-dose suvorexant ( MK-4305) to treat insomnia at the SLEEP 2012 meeting in Boston. In the first tr...